CARsgen Therapeutics Holdings Ltd
HKEX:2171

Watchlist Manager
CARsgen Therapeutics Holdings Ltd Logo
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Watchlist
Price: 8.36 HKD -0.71% Market Closed
Market Cap: 4.8B HKD
Have any thoughts about
CARsgen Therapeutics Holdings Ltd?
Write Note

CARsgen Therapeutics Holdings Ltd
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CARsgen Therapeutics Holdings Ltd
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Other Current Liabilities
ÂĄ30.9m
CAGR 3-Years
30%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Current Liabilities
ÂĄ1.5B
CAGR 3-Years
-7%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Other Current Liabilities
ÂĄ1.8B
CAGR 3-Years
38%
CAGR 5-Years
74%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Current Liabilities
ÂĄ1.9B
CAGR 3-Years
53%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Current Liabilities
ÂĄ2.5B
CAGR 3-Years
23%
CAGR 5-Years
55%
CAGR 10-Years
58%
Imeik Technology Development Co Ltd
SZSE:300896
Other Current Liabilities
ÂĄ121.8m
CAGR 3-Years
33%
CAGR 5-Years
72%
CAGR 10-Years
N/A
No Stocks Found

CARsgen Therapeutics Holdings Ltd
Glance View

Market Cap
4.8B HKD
Industry
Biotechnology

CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.

Intrinsic Value
12.81 HKD
Undervaluation 35%
Intrinsic Value
Price

See Also

What is CARsgen Therapeutics Holdings Ltd's Other Current Liabilities?
Other Current Liabilities
30.9m CNY

Based on the financial report for Dec 31, 2023, CARsgen Therapeutics Holdings Ltd's Other Current Liabilities amounts to 30.9m CNY.

What is CARsgen Therapeutics Holdings Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 3Y
30%

Over the last year, the Other Current Liabilities growth was 151%. The average annual Other Current Liabilities growth rates for CARsgen Therapeutics Holdings Ltd have been 30% over the past three years .

Back to Top